Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

GLP-1 based therapies and disease course of inflammatory bowel disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Successful glucose lowering therapy triumphs in heart failure

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Implementation of indicator condition guided HIV testing still lagging behind the evidence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oral tranexamic acid and thrombosis risk in women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Thromboembolic and bleeding complications following primary total knee arthroplasty: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Using machine learning for predicting intensive care unit resource use during the COVID-19 pandemic in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Fractures and Osteoporosis in Patients With Diabetes With Charcot Foot

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: The disease course of inflammatory bowel disease (IBD) following treatment with glucagon-like peptide (GLP)-1 based therapies is unclear. The aim of this study was to examine the disease course of IBD in patients treated with GLP-1 based therapies compared with treatment with other antidiabetics.

Methods: Using nationwide Danish registries, we identified patients with IBD and type 2 diabetes who received antidiabetic treatment between 1 January 2007 and 31 March 2019. The primary outcome was a composite of the need for oral corticosteroids, tumour necrosis factor-α inhibitors, IBD-related hospitalisation, or IBD-related surgery. In the setting of a new-user active comparator design, we used Poisson regression to estimate incidence rate ratios (IRR) comparing treatment with GLP-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors with other antidiabetic therapies. The analyses were adjusted for age, sex, calendar year, IBD severity, and metformin use.

Findings: We identified 3751 patients with a diagnosis of IBD and type 2 diabetes and with a prescription of an antidiabetic drug (GLP-1 receptor agonists/DPP-4 inhibitors: 982 patients; other antidiabetic treatment: 2769 patients). The adjusted IRR of the composite outcome was 0·52 (95% CI: 0·42-0·65) for patients exposed to GLP-1 receptor agonists/DPP-4 inhibitors compared with patients exposed to other antidiabetics.

Interpretation: In patients with IBD and type 2 diabetes, we observed a lower risk of adverse clinical events amongst patients treated with GLP-1 based therapies compared with treatment with other antidiabetics. These findings suggest that treatment with GLP-1 based therapies may improve the disease course of IBD.

OriginalsprogEngelsk
Artikelnummer100979
TidsskriftEClinicalMedicine
Vol/bind37
Sider (fra-til)100979
ISSN2589-5370
DOI
StatusUdgivet - jul. 2021

ID: 67051868